Categories: BioTechDrugITNonprofitProductResearch
ProJenX is a clinical-stage biotechnology company with novel, brain-penetrant targeted therapies to address debilitating brain diseases, with an initial focus on ALS.
Investors 1
Funding Rounds 1
| Date | Series | Amount | Investors |
| 02.11.2023 | Series A | $15M | - |
Mentions in press and media 5
| Date | Title | Description |
| 29.08.2024 | The Cosmic Dilemma: Are We Alone in the Universe? | The night sky has always been a canvas of wonder. Stars twinkle like distant dreams, whispering secrets of the cosmos. Yet, beneath this beauty lies a profound question: Are we alone? Recent research offers a fresh perspective on this age-o... |
| 27.08.2024 | ProJenX Announces Formation of Clinical Advisory Board | NEW YORK, Aug. 27, 2024 /PRNewswire/ -- ProJenX, Inc., a clinical-stage biotechnology company developing novel, brain-penetrant therapies targeting biologically-defined pathways for the treatment of amyotrophic lateral sclerosis (ALS) and o... |
| 02.11.2023 | ProJenX Holds Initial Closing of $15M Series A Financing | ProJenX, Inc., a NYC-based clinical-stage biotechnology company, announced the initial closing of a $15m Series A financing.
The round was led by Medical Excellence Capital, which also led the company’s seed financing round and created ProJ... |
| 09.09.2022 | Meet John Prufeta, General Partner of Medical Excellence Capital | MEC invests in cell therapy, gene therapy, regenerative medicine, synthetic biology, and AI
Venture capital used to be a cottage industry, with very few investing in tomorrow's products and services. Oh, how times have changed! While there ... |
| - | ProJenX | - |
Reviews 0
